Novavax’s leadership, including CEO John Jacobs, opened the company’s 2026 outlook at the 44th Annual J.P. Morgan Healthcare Conference by emphasizing the strategic importance of its protein-based vaccine platform and robust clinical pipeline. Jacobs reiterated forward-looking projections first disclosed in November filings, forecasting a 30% year-over-year increase in manufacturing capacity by mid-2026. He highlighted two late-stage respiratory vaccine candidates expected to enter regulatory review in the third quarter and detailed partnerships that will expand fill-and-finish operations in both North America and Europe. Investors should note Novavax’s planned capital raise to support these initiatives, which involves up to $200 million in equity issuance subject to market conditions and shareholder approval.

On the Monday trading session following the conference, Novavax shares experienced a sharper decline than the broader biotechnology index, dropping by 5.54% despite no new negative announcements. Trading volume was 40% above its 30-day average, suggesting institutional repositioning ahead of upcoming data releases. Contrastingly, in the subsequent session, shares rebounded with an 11.9% surge, driven by upward revisions from two independent analyst firms that increased the 2026 revenue forecast by an average of 15%. The combination of elevated volume and rapid sentiment shifts underscores the market’s high sensitivity to clinical milestones and financing updates, factors critical for investors assessing risk exposure in the coming quarters.